Obseva Logo4 (00000002).jpg
ObsEva Announces First Quarter 2021 Financial Results and Business Update
May 06, 2021 01:00 ET | ObsEva SA
  -Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty® for endometriosis: Readout from...
Obseva Logo4 (00000002).jpg
ObsEva appoints Clive Bertram as Chief Commercial Officer
May 06, 2021 00:55 ET | ObsEva SA
GENEVA, Switzerland and BOSTON, MA – May 6, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
Obseva Logo4 (00000002).jpg
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
May 04, 2021 01:00 ET | ObsEva SA
  - EDELWEISS 3 trial of Yselty® expected to report topline data as planned in Q4:21-   GENEVA, Switzerland and BOSTON, MA – May 4, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a...
Obseva Logo4 (00000002).jpg
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
April 30, 2021 16:05 ET | ObsEva SA
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
Obseva Logo4 (00000002).jpg
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
April 27, 2021 01:00 ET | ObsEva SA
-Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 -   GENEVA, Switzerland and BOSTON, MA – April...
Obseva Logo4 (00000002).jpg
ObsEva Annual General Meeting 2021
April 22, 2021 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – April 22, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
Obseva Logo4 (00000002).jpg
ObsEva Announces Year End 2020 Financial Results and Business Update
March 05, 2021 01:00 ET | ObsEva SA
-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3...
Obseva Logo4 (00000002).jpg
ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
Obseva Logo4 (00000002).jpg
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 17, 2021 01:00 ET | ObsEva SA
  Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
Obseva Logo4 (00000002).jpg
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
February 11, 2021 01:00 ET | ObsEva SA
  Geneva, Switzerland and Boston, MA – Thursday 11 February, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and...